{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:24:56Z","timestamp":1787289896247,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.gore.2026.102175","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:49:37Z","timestamp":1785167377000},"page":"102175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib"],"prefix":"10.1016","volume":"66","author":[{"given":"Francis Yew Fu","family":"Tieng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Kisha","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po Lin","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102175_bb0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/medicina60071085","article-title":"Uterine mesenchymal tumors: updates on pathology, molecular landscape, and therapeutics","volume":"60","author":"Alodaini","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.gore.2026.102175_bb0010","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1634\/theoncologist.2018-0095","article-title":"Systemic treatment of metastatic\/recurrent uterine Leiomyosarcoma: a changing paradigm","volume":"23","author":"Arend","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.gore.2026.102175_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of Lorlatinib: cumulative incidences of CNS and non-CNS progression with Lorlatinib in patients with previously treated ALK-positive non-small-cell lung Cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target. Oncol."},{"key":"10.1016\/j.gore.2026.102175_bb0020","article-title":"Recurrent uterine inflammatory Myofibroblastic tumor previously managed as Leiomyosarcoma has sustained response to Alectinib","volume":"43","author":"Carballo","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.gore.2026.102175_bb0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine Leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.gore.2026.102175_bb0030","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor Crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102175_bb0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/1541-7786.MCR-18-1075","article-title":"Discovery and characterization of recurrent, targetable ALK fusions in Leiomyosarcoma","volume":"17","author":"Davis","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.gore.2026.102175_bb0040","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/cancers16050938","article-title":"The future of targeted therapy for Leiomyosarcoma","volume":"16","author":"Denu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gore.2026.102175_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244233","article-title":"Uterine Leiomyosarcoma: a rare clinical entity","volume":"14","author":"Dunphy","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.gore.2026.102175_bb0050","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor Ceritinib overcomes Crizotinib resistance in non-small cell lung Cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gore.2026.102175_bb0055","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001115","article-title":"ALK: a tyrosine kinase target for Cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.gore.2026.102175_bb0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s44276-025-00190-x","article-title":"Transcriptome profiling of uterine Leiomyosarcomas identifies a leiomyoma-like expression pattern that indicates better survival","volume":"3","author":"Khamaiseh","year":"2025","journal-title":"BJC Rep"},{"key":"10.1016\/j.gore.2026.102175_bb0065","article-title":"Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy","volume":"37","author":"Kyi","year":"2021","journal-title":"Gynecol Oncol. Rep."},{"key":"10.1016\/j.gore.2026.102175_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gore.2026.102175_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010010","article-title":"Novel therapeutics in soft tissue sarcoma","volume":"17","author":"Mavroeidis","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.gore.2026.102175_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the Pan-Cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"Npj precis. Onc"},{"key":"10.1016\/j.gore.2026.102175_bb0085","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2026.102175_bb0090","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1159\/000516758","article-title":"Uterine Leiomyosarcoma with FN1-anaplastic lymphoma kinase fusion responsive to Alectinib and Lorlatinib","volume":"14","author":"Testa","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.gore.2026.102175_bb0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in Cancer: from function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat. Rev. Cancer"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:49:19Z","timestamp":1787287759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S2352578926001554"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102175","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102175"}}